UBL7
geneOn this page
Also known as BMSC-UbPMGC14421
Summary
UBL7 (ubiquitin like 7, HGNC:28221) is a protein-coding gene on chromosome 15q24.1, encoding Ubiquitin-like protein 7 (Q96S82). Interferon-stimulated protein that positively regulates RNA virus-triggered innate immune signaling.
Enables protein-macromolecule adaptor activity. Involved in antiviral innate immune response. Is active in cytoplasm.
Source: NCBI Gene 84993 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 63 total
- MANE Select transcript:
NM_032907
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28221 |
| Approved symbol | UBL7 |
| Name | ubiquitin like 7 |
| Location | 15q24.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | BMSC-UbP, MGC14421 |
| Ensembl gene | ENSG00000138629 |
| Ensembl biotype | protein_coding |
| OMIM | 609748 |
| Entrez | 84993 |
Gene structure
Transcript identifiers
Ensembl transcripts: 45 — 45 protein_coding
ENST00000361351, ENST00000395081, ENST00000563081, ENST00000564488, ENST00000565130, ENST00000565335, ENST00000565494, ENST00000566365, ENST00000567435, ENST00000902154, ENST00000902155, ENST00000902156, ENST00000902157, ENST00000902158, ENST00000902159, ENST00000902160, ENST00000902161, ENST00000902162, ENST00000902163, ENST00000902164, ENST00000902165, ENST00000940643, ENST00000940644, ENST00000940645, ENST00000940646, ENST00000940647, ENST00000940648, ENST00000940649, ENST00000940650, ENST00000940651, ENST00000940652, ENST00000940653, ENST00000940654, ENST00000940655, ENST00000940656, ENST00000940657, ENST00000940658, ENST00000940659, ENST00000940660, ENST00000940661, ENST00000947580, ENST00000947581, ENST00000947582, ENST00000947583, ENST00000947584
RefSeq mRNA: 6 — MANE Select: NM_032907
NM_001286739, NM_001286740, NM_001286741, NM_001286742, NM_032907, NM_201265
CCDS: CCDS10263
Canonical transcript exons
ENST00000395081 — 11 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000931902 | 74448478 | 74448600 |
| ENSE00000931903 | 74449186 | 74449353 |
| ENSE00000931904 | 74449626 | 74449675 |
| ENSE00000931905 | 74449936 | 74450069 |
| ENSE00000931907 | 74451436 | 74451520 |
| ENSE00000931908 | 74452296 | 74452378 |
| ENSE00000931909 | 74456552 | 74456671 |
| ENSE00001110742 | 74445977 | 74446227 |
| ENSE00001259805 | 74458684 | 74458896 |
| ENSE00001520566 | 74461037 | 74461160 |
| ENSE00003606483 | 74450802 | 74450859 |
Expression profiles
Bgee: expression breadth ubiquitous, 134 present calls, max score 96.92.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.4379 / max 336.6392, expressed in 1817 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 150915 | 29.4379 | 1817 |
Top tissues by expression
134 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| primary visual cortex | UBERON:0002436 | 96.92 | gold quality |
| prefrontal cortex | UBERON:0000451 | 96.70 | gold quality |
| apex of heart | UBERON:0002098 | 96.62 | gold quality |
| frontal cortex | UBERON:0001870 | 96.30 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 96.02 | gold quality |
| gastrocnemius | UBERON:0001388 | 95.95 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 95.91 | gold quality |
| right frontal lobe | UBERON:0002810 | 95.87 | gold quality |
| cerebral cortex | UBERON:0000956 | 95.63 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 95.63 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 95.56 | gold quality |
| blood | UBERON:0000178 | 95.53 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 95.47 | gold quality |
| muscle of leg | UBERON:0001383 | 95.32 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 94.81 | gold quality |
| Ammon’s horn | UBERON:0001954 | 94.52 | gold quality |
| heart left ventricle | UBERON:0002084 | 94.51 | gold quality |
| putamen | UBERON:0001874 | 94.44 | gold quality |
| amygdala | UBERON:0001876 | 94.34 | gold quality |
| temporal lobe | UBERON:0001871 | 94.33 | gold quality |
| substantia nigra | UBERON:0002038 | 94.32 | gold quality |
| monocyte | CL:0000576 | 94.16 | gold quality |
| leukocyte | CL:0000738 | 94.14 | gold quality |
| right testis | UBERON:0004534 | 94.05 | gold quality |
| granulocyte | CL:0000094 | 93.99 | gold quality |
| left testis | UBERON:0004533 | 93.92 | gold quality |
| muscle tissue | UBERON:0002385 | 93.89 | gold quality |
| brain | UBERON:0000955 | 93.82 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 93.72 | gold quality |
| heart | UBERON:0000948 | 93.63 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 7.40 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
18 targeting UBL7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-4725-3P | 99.96 | 69.53 | 2520 |
| HSA-MIR-6780B-5P | 99.96 | 69.60 | 2562 |
| HSA-MIR-2110 | 99.96 | 66.68 | 1930 |
| HSA-MIR-4731-5P | 99.89 | 67.23 | 2537 |
| HSA-MIR-4271 | 99.88 | 68.32 | 2244 |
| HSA-MIR-4306 | 99.72 | 70.50 | 3630 |
| HSA-MIR-3202 | 99.66 | 67.70 | 2737 |
| HSA-MIR-3612 | 99.45 | 66.02 | 1333 |
| HSA-MIR-650 | 99.45 | 65.77 | 1309 |
| HSA-MIR-185-5P | 99.35 | 68.60 | 2497 |
| HSA-MIR-6731-5P | 99.28 | 67.42 | 2375 |
| HSA-MIR-8085 | 99.28 | 67.56 | 2362 |
| HSA-MIR-6814-5P | 99.03 | 66.68 | 1273 |
| HSA-MIR-4772-3P | 98.04 | 65.60 | 1203 |
| HSA-MIR-450A-2-3P | 97.91 | 67.56 | 1459 |
| HSA-MIR-6836-3P | 97.08 | 64.99 | 712 |
| HSA-MIR-591 | 96.29 | 68.16 | 611 |
Literature-anchored findings (GeneRIF, showing 2)
- BMSC-UbP might play roles in regulation of BMSC function or cell differentiation through an evocator- and cell-specific pattern. (PMID:12644319)
- the solution NMR structure of the ubiquitin-associated domain of the human BMSC-UbP protein and its complex with ubiquitin (PMID:16731964)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | ubl7a | ENSDARG00000024229 |
| danio_rerio | ubl7b | ENSDARG00000040286 |
| mus_musculus | Ubl7 | ENSMUSG00000055720 |
| rattus_norvegicus | Ubl7 | ENSRNOG00000007442 |
| drosophila_melanogaster | CG31528 | FBGN0051528 |
Paralogs (5): UBQLN1 (ENSG00000135018), UBQLN4 (ENSG00000160803), UBQLNL (ENSG00000175518), UBQLN3 (ENSG00000175520), UBQLN2 (ENSG00000188021)
Protein
Protein identifiers
Ubiquitin-like protein 7 — Q96S82 (reviewed: Q96S82)
Alternative names: Bone marrow stromal cell ubiquitin-like protein, Ubiquitin-like protein SB132
All UniProt accessions (5): Q96S82, H3BSE0, H3BSQ2, H3BUV9, H3BV23
UniProt curated annotations — full annotation on UniProt →
Function. Interferon-stimulated protein that positively regulates RNA virus-triggered innate immune signaling. Mechanistically, promotes ‘Lys-27’-linked polyubiquitination of MAVS through TRIM21 leading to enhanced the IFN signaling pathway.
Subunit / interactions. Binds ubiquitin. Interacts with MAVS; this interaction enhances TRIM21-dependent ‘Lys-27’-linked polyubiquitination of MAVS.
Tissue specificity. Ubiquitous. Highly expressed in heart, skeletal muscle, testis, thyroid and adrenal gland.
Post-translational modifications. Deubiquitinated by OTUD4 which stabilizes UBL7 expression.
Induction. By type I interferon. Down-regulated by phorbol myristate acetate (PMA) in bone marrow stroma cells.
RefSeq proteins (6): NP_001273668, NP_001273669, NP_001273670, NP_001273671, NP_116296, NP_957717 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000626 | Ubiquitin-like_dom | Domain |
| IPR009060 | UBA-like_sf | Homologous_superfamily |
| IPR015496 | Ubiquilin | Family |
| IPR015940 | UBA | Domain |
| IPR029071 | Ubiquitin-like_domsf | Homologous_superfamily |
| IPR047877 | UBL7_Ubl | Domain |
| IPR047878 | UBL7_UBA | Domain |
Pfam: PF00240
UniProt features (15 total): compositionally biased region 4, helix 3, domain 2, sequence conflict 2, chain 1, turn 1, region of interest 1, modified residue 1
Structure
Experimental structures (PDB)
2 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 2CWB | SOLUTION NMR | |
| 2DEN | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q96S82-F1 | 67.70 | 0.00 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 230
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 77 (showing top):
GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_DEFENSE_RESPONSE_TO_VIRUS, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GOBP_PROTEIN_CATABOLIC_PROCESS, GOBP_RESPONSE_TO_VIRUS, GRYDER_PAX3FOXO1_TOP_ENHANCERS, GOBP_PROTEOLYSIS, GSE13887_HEALTHY_VS_LUPUS_RESTING_CD4_TCELL_UP, GRYDER_PAX3FOXO1_ENHANCERS_KO_DOWN, DUAN_PRDM5_TARGETS, GOMF_POLYUBIQUITIN_MODIFICATION_DEPENDENT_PROTEIN_BINDING, GOMF_MODIFICATION_DEPENDENT_PROTEIN_BINDING, E2F2_TARGET_GENES, FOXJ2_TARGET_GENES
GO Biological Process (6): ubiquitin-dependent protein catabolic process (GO:0006511), antiviral innate immune response (GO:0140374), immune system process (GO:0002376), protein K27-linked ubiquitination (GO:0044314), innate immune response (GO:0045087), defense response to virus (GO:0051607)
GO Molecular Function (3): protein-macromolecule adaptor activity (GO:0030674), polyubiquitin modification-dependent protein binding (GO:0031593), protein binding (GO:0005515)
GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| protein ubiquitination | 1 |
| modification-dependent protein catabolic process | 1 |
| innate immune response | 1 |
| defense response to virus | 1 |
| biological_process | 1 |
| protein polyubiquitination | 1 |
| immune response | 1 |
| defense response to symbiont | 1 |
| defense response | 1 |
| response to virus | 1 |
| protein binding | 1 |
| molecular adaptor activity | 1 |
| modification-dependent protein binding | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
Protein interactions and networks
STRING
3510 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| UBL7 | UBQLN2 | Q9UHD9 | 836 |
| UBL7 | UBQLN1 | Q9UMX0 | 828 |
| UBL7 | ZNF428 | Q96B54 | 709 |
| UBL7 | CIAPIN1 | Q6FI81 | 629 |
| UBL7 | CCDC33 | Q8N5R6 | 629 |
| UBL7 | MAS1 | P04201 | 624 |
| UBL7 | SLC44A3 | Q8N4M1 | 534 |
| UBL7 | CLK3 | P49761 | 496 |
| UBL7 | DDX49 | Q9Y6V7 | 493 |
| UBL7 | PRMT2IP | Q6ZRI6 | 479 |
| UBL7 | UBAC1 | Q9BSL1 | 478 |
| UBL7 | UBL4A | P11441 | 477 |
| UBL7 | NUB1 | Q9Y5A7 | 469 |
| UBL7 | RWDD1 | Q9H446 | 462 |
| UBL7 | ISLR2 | Q6UXK2 | 452 |
IntAct
54 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| VBP1 | UBL7 | psi-mi:“MI:0915”(physical association) | 0.830 |
| UBL7 | VBP1 | psi-mi:“MI:0915”(physical association) | 0.830 |
| UBL7 | AP1G1 | psi-mi:“MI:0915”(physical association) | 0.720 |
| AP1G1 | UBL7 | psi-mi:“MI:0915”(physical association) | 0.720 |
| UBL7 | ERCC1 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ERCC1 | UBL7 | psi-mi:“MI:0915”(physical association) | 0.670 |
| VBP1 | PFDN6 | psi-mi:“MI:0914”(association) | 0.640 |
| UBL7 | CAPN7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CAPN7 | UBL7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| UBL7 | psi-mi:“MI:0915”(physical association) | 0.560 | |
| UBL7 | psi-mi:“MI:0915”(physical association) | 0.560 | |
| ERCC1 | UBL7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RXRB | UBL7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ESRRG | UBL7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KDELR1 | TRAFD1 | psi-mi:“MI:0914”(association) | 0.530 |
| UBL7 | psi-mi:“MI:0915”(physical association) | 0.520 | |
| UBL7 | psi-mi:“MI:0915”(physical association) | 0.520 |
BioGRID (100): UBL7 (Two-hybrid), UBL7 (Two-hybrid), UBL7 (Two-hybrid), UBL7 (Two-hybrid), UBB (Affinity Capture-MS), UBE4B (Affinity Capture-MS), AMY1C (Affinity Capture-MS), HDAC6 (Affinity Capture-MS), UBL7 (Two-hybrid), UBL7 (Two-hybrid), UBL7 (Affinity Capture-MS), DDX3X (Co-fractionation), HSPA4L (Co-fractionation), SNF8 (Co-fractionation), TLN2 (Co-fractionation)
ESM2 similar proteins: A1CDT9, A1DCU5, A3KMV2, F4JPR7, G5EFF7, O17453, O48726, O74803, P32628, P48510, P54725, P54726, P54727, P54728, P55035, Q0CJ13, Q0U3Y6, Q10169, Q1DNB9, Q1EBV4, Q28DG7, Q29RK4, Q2H085, Q2KIS3, Q2USD7, Q40742, Q4KMA2, Q4WGS4, Q54LV1, Q5AY89, Q5XIR9, Q5ZJI9, Q6NXA9, Q6NYI0, Q7K2G1, Q7S906, Q7ZXQ3, Q84L30, Q84L31, Q84L32
Diamond homologs: Q2KIS3, Q91W67, Q96S82, Q9UHD9
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
63 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 43 |
| Likely benign | 2 |
| Benign | 2 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1566 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 15:74449180:TCATA:T | donor_loss | 1.0000 |
| 15:74449181:CATAC:C | donor_loss | 1.0000 |
| 15:74449182:ATAC:A | donor_loss | 1.0000 |
| 15:74449183:TAC:T | donor_loss | 1.0000 |
| 15:74449185:C:CG | donor_loss | 1.0000 |
| 15:74449349:GTGTT:G | acceptor_gain | 1.0000 |
| 15:74449350:TGTT:T | acceptor_gain | 1.0000 |
| 15:74449351:GTT:G | acceptor_gain | 1.0000 |
| 15:74449352:TT:T | acceptor_gain | 1.0000 |
| 15:74449353:TCTGG:T | acceptor_loss | 1.0000 |
| 15:74449354:C:CC | acceptor_gain | 1.0000 |
| 15:74449624:A:AC | donor_gain | 1.0000 |
| 15:74449625:C:CC | donor_gain | 1.0000 |
| 15:74449931:CTCA:C | donor_loss | 1.0000 |
| 15:74449933:CA:C | donor_loss | 1.0000 |
| 15:74450065:CCAAC:C | acceptor_gain | 1.0000 |
| 15:74450066:CAAC:C | acceptor_gain | 1.0000 |
| 15:74450066:CAACC:C | acceptor_gain | 1.0000 |
| 15:74450070:CTA:C | acceptor_loss | 1.0000 |
| 15:74450071:T:C | acceptor_loss | 1.0000 |
| 15:74451431:CTTA:C | donor_loss | 1.0000 |
| 15:74451432:TTACC:T | donor_loss | 1.0000 |
| 15:74451433:TACCA:T | donor_loss | 1.0000 |
| 15:74451434:A:AC | donor_gain | 1.0000 |
| 15:74451434:A:AT | donor_loss | 1.0000 |
| 15:74451435:C:CA | donor_loss | 1.0000 |
| 15:74451435:C:CC | donor_gain | 1.0000 |
| 15:74451521:C:CC | acceptor_gain | 1.0000 |
| 15:74456550:AC:A | donor_gain | 1.0000 |
| 15:74456551:CC:C | donor_gain | 1.0000 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000045651 (15:74452328 C>A,G,T), RS1000086766 (15:74445768 T>TG), RS1000168958 (15:74456971 A>G), RS1000401120 (15:74461624 T>C), RS1000410621 (15:74461460 C>G,T), RS1000636486 (15:74451143 C>T), RS1000841447 (15:74456182 C>T), RS1001134963 (15:74450101 G>A), RS1001225368 (15:74462776 C>A,T), RS1001334173 (15:74462034 A>G), RS1001618441 (15:74462418 C>A), RS1002180103 (15:74462096 A>C,G), RS1002294676 (15:74462346 C>G), RS1002372471 (15:74449069 C>T), RS1002476826 (15:74456043 T>C,G)
Disease associations
OMIM: gene MIM:609748 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
4 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004412_7 | Craniofacial microsomia | 1.000000e-23 |
| GCST004865_16 | Itch intensity from mosquito bite adjusted by bite size | 6.000000e-08 |
| GCST009391_1925 | Metabolite levels | 7.000000e-06 |
| GCST90002382_325 | Eosinophil percentage of white cells | 3.000000e-09 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0008377 | mosquito bite reaction itch intensity measurement |
| EFO:0008378 | mosquito bite reaction size measurement |
| EFO:0010464 | beta-aminoisobutyric acid measurement |
| EFO:0007991 | eosinophil percentage of leukocytes |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
26 total (human), top 26 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| FR900359 | increases phosphorylation | 1 |
| bisphenol F | increases expression, affects cotreatment | 1 |
| triphenyl phosphate | affects expression | 1 |
| pirinixic acid | increases activity, affects binding, decreases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| coumarin | increases phosphorylation | 1 |
| beta-methylcholine | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| K 7174 | decreases expression | 1 |
| 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide | decreases expression, decreases reaction | 1 |
| jinfukang | increases expression, affects cotreatment | 1 |
| Sunitinib | decreases expression | 1 |
| Vehicle Emissions | decreases expression, decreases reaction | 1 |
| Cisplatin | affects cotreatment, increases expression | 1 |
| Dexamethasone | increases expression, affects cotreatment | 1 |
| Estradiol | increases expression | 1 |
| Hydrogen Peroxide | affects expression | 1 |
| Indomethacin | affects cotreatment, increases expression | 1 |
| Lead | affects methylation | 1 |
| Thiram | decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| 1-Methyl-3-isobutylxanthine | affects cotreatment, increases expression | 1 |
| Cyclosporine | decreases expression | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
| Lactic Acid | decreases expression | 1 |
| Particulate Matter | decreases expression, decreases reaction | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): craniofacial microsomia